Oxaliplatin Accord (Oxaliplatin)

Oxaliplatin Accord is a platinum‑based chemotherapy used in the treatment of cancers that involve the gastrointestinal tract and related pathways.

• Colorectal cancer: improves survival rates when combined with fluorouracil and leucovorin.
• Gastric cancer: used as part of combination regimens for advanced disease.
• Pancreatic cancer: contributes to tumor response in multi‑drug protocols.
• Ovarian cancer: employed in certain platinum‑sensitive relapse settings.
• Esophageal cancer: added to chemotherapeutic schedules for locally advanced cases.

• Oxaliplatin forms a reactive platinum complex that covalently binds to DNA bases, creating intra‑ and interstrand cross‑links that inhibit DNA replication and transcription. This DNA damage triggers cellular apoptosis, particularly in rapidly dividing tumor cells, while sparing most normal tissues at therapeutic doses.

Oxaliplatin Accord may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Diarrhoea: loose stools that may require supportive care.
• Fatigue: general tiredness affecting daily activities.
• Thrombocytopenia: reduced platelet count increasing bleeding risk.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis or bronchospasm.
• Acute neurotoxicity: sudden onset of muscle cramps or spasms.
• Hematologic toxicity: neutropenia or severe anemia.
• Cardiotoxicity: rare arrhythmias or myocardial injury.
• Renal impairment: acute kidney injury in susceptible patients.

When handling Oxaliplatin Accord, clinicians should observe specific safety measures and patient monitoring protocols.

• Renal function assessment: evaluate baseline creatinine and adjust if impaired.
• Hepatic function monitoring: check liver enzymes before and during therapy.
• Neuropathy surveillance: assess for sensory changes at each visit.
• Hematologic monitoring: perform regular CBCs to detect cytopenias.
• Pregnancy and lactation warning: avoid use unless benefits outweigh risks.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, requiring careful review.

Major Interactions (Avoid)

• Nephrotoxic agents: concurrent use with aminoglycosides may increase kidney injury risk.
• Myelosuppressive chemotherapy: combined regimens can amplify bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Anticoagulants: may heighten bleeding tendency due to thrombocytopenia.\n- Antiemetic agents: some may alter oxaliplatin pharmacokinetics.
• NSAIDs: can affect platelet function and increase gastrointestinal toxicity.
• Vitamin C high‑dose supplements: may reduce platinum‑drug efficacy.
• CYP 3‑ ?